Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Transplantation | 23 | 2020 | 1307 | 2.030 |
Why?
|
Cystic Fibrosis | 20 | 2024 | 1283 | 1.640 |
Why?
|
Bronchiolitis Obliterans | 9 | 2014 | 213 | 1.580 |
Why?
|
Delayed Graft Function | 1 | 2019 | 53 | 0.620 |
Why?
|
Trachea | 7 | 2005 | 1090 | 0.490 |
Why?
|
Graft Rejection | 9 | 2018 | 4481 | 0.450 |
Why?
|
Lymphoproliferative Disorders | 3 | 2013 | 531 | 0.410 |
Why?
|
Mannose-Binding Lectin | 1 | 2012 | 145 | 0.370 |
Why?
|
Histocompatibility Testing | 1 | 2010 | 716 | 0.320 |
Why?
|
Herpesvirus 4, Human | 2 | 2013 | 1076 | 0.310 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2013 | 614 | 0.280 |
Why?
|
HLA Antigens | 2 | 2010 | 1331 | 0.280 |
Why?
|
Stem Cell Transplantation | 2 | 2006 | 1600 | 0.270 |
Why?
|
Graft Survival | 4 | 2018 | 3843 | 0.260 |
Why?
|
Cyclosporine | 2 | 2005 | 776 | 0.250 |
Why?
|
Lung Diseases | 3 | 2006 | 1910 | 0.250 |
Why?
|
Respiratory Mucosa | 4 | 2014 | 436 | 0.240 |
Why?
|
Antibodies | 1 | 2013 | 2415 | 0.240 |
Why?
|
Hyperglycemia | 2 | 2024 | 1375 | 0.230 |
Why?
|
Achromobacter | 1 | 2022 | 8 | 0.210 |
Why?
|
Sputum | 1 | 2024 | 505 | 0.200 |
Why?
|
Stem Cells | 2 | 2006 | 3517 | 0.200 |
Why?
|
Transplantation, Heterotopic | 1 | 2002 | 175 | 0.200 |
Why?
|
Transplantation Immunology | 2 | 2003 | 537 | 0.190 |
Why?
|
Metagenomics | 1 | 2024 | 463 | 0.180 |
Why?
|
Aminophenols | 1 | 2021 | 87 | 0.180 |
Why?
|
Hyperoxia | 1 | 2022 | 259 | 0.180 |
Why?
|
Growth Substances | 1 | 2002 | 759 | 0.170 |
Why?
|
Bacteriophages | 1 | 2022 | 378 | 0.160 |
Why?
|
Cell Division | 2 | 2005 | 4451 | 0.160 |
Why?
|
Transplantation, Homologous | 7 | 2010 | 4822 | 0.150 |
Why?
|
Hypertension, Pulmonary | 2 | 2020 | 1592 | 0.150 |
Why?
|
Quinolones | 1 | 2021 | 378 | 0.140 |
Why?
|
Epithelium | 1 | 2002 | 1603 | 0.140 |
Why?
|
Referral and Consultation | 2 | 2020 | 3608 | 0.140 |
Why?
|
Patient Care Management | 1 | 2020 | 303 | 0.140 |
Why?
|
Airway Management | 1 | 2020 | 312 | 0.130 |
Why?
|
Hypoglycemia | 1 | 2024 | 883 | 0.130 |
Why?
|
Pulmonary Fibrosis | 2 | 2018 | 505 | 0.130 |
Why?
|
Transplantation, Isogeneic | 3 | 2002 | 249 | 0.130 |
Why?
|
Blood Glucose Self-Monitoring | 3 | 2024 | 468 | 0.130 |
Why?
|
Up-Regulation | 2 | 2014 | 4111 | 0.120 |
Why?
|
Lung | 4 | 2022 | 9979 | 0.120 |
Why?
|
Bone Density | 4 | 2021 | 3546 | 0.120 |
Why?
|
Bone and Bones | 2 | 2021 | 2568 | 0.110 |
Why?
|
Staphylococcal Infections | 1 | 2022 | 1401 | 0.110 |
Why?
|
Regeneration | 1 | 2002 | 1505 | 0.110 |
Why?
|
Mice, Inbred BALB C | 7 | 2006 | 6200 | 0.110 |
Why?
|
Lymphocytes | 4 | 2014 | 2603 | 0.110 |
Why?
|
HLA-A Antigens | 2 | 2010 | 223 | 0.100 |
Why?
|
Cold Ischemia | 1 | 2012 | 70 | 0.100 |
Why?
|
Radiation Injuries, Experimental | 1 | 2012 | 88 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 1 | 2000 | 1803 | 0.100 |
Why?
|
Postoperative Complications | 2 | 2013 | 15637 | 0.090 |
Why?
|
Hyaluronic Acid | 1 | 2014 | 484 | 0.090 |
Why?
|
Bone Diseases, Endocrine | 1 | 2009 | 2 | 0.090 |
Why?
|
Chronic Disease | 4 | 2019 | 9319 | 0.090 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2024 | 3417 | 0.080 |
Why?
|
HLA-A3 Antigen | 1 | 2008 | 34 | 0.080 |
Why?
|
HLA-DR Antigens | 1 | 2010 | 606 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 4567 | 0.080 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2013 | 668 | 0.080 |
Why?
|
Respiratory System | 2 | 2024 | 562 | 0.070 |
Why?
|
Humans | 34 | 2024 | 761222 | 0.070 |
Why?
|
Quality of Life | 2 | 2020 | 13367 | 0.070 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2012 | 583 | 0.070 |
Why?
|
Palliative Care | 2 | 2020 | 3599 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2020 | 3253 | 0.070 |
Why?
|
Critical Care | 1 | 2020 | 2696 | 0.070 |
Why?
|
Lung Injury | 1 | 2012 | 422 | 0.070 |
Why?
|
Cytokines | 3 | 2006 | 7386 | 0.070 |
Why?
|
Bronchi | 2 | 2014 | 843 | 0.070 |
Why?
|
Bacteria | 3 | 2024 | 2190 | 0.070 |
Why?
|
Propionibacterium acnes | 1 | 2006 | 59 | 0.070 |
Why?
|
Apoptosis | 1 | 2002 | 9478 | 0.060 |
Why?
|
Bronchoalveolar Lavage Fluid | 2 | 2024 | 753 | 0.060 |
Why?
|
Immunosuppressive Agents | 3 | 2004 | 4190 | 0.060 |
Why?
|
Phenotype | 2 | 2019 | 16575 | 0.060 |
Why?
|
Osteocalcin | 2 | 2003 | 274 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5842 | 0.060 |
Why?
|
Adult | 19 | 2024 | 221120 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 4014 | 0.060 |
Why?
|
Tissue Donors | 2 | 2013 | 2335 | 0.060 |
Why?
|
Blood Glucose | 3 | 2024 | 6392 | 0.060 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2010 | 1348 | 0.060 |
Why?
|
Bionics | 1 | 2024 | 46 | 0.060 |
Why?
|
Freezing | 1 | 2024 | 311 | 0.060 |
Why?
|
CD40 Ligand | 1 | 2005 | 524 | 0.060 |
Why?
|
Mice | 11 | 2014 | 81330 | 0.050 |
Why?
|
Mice, Inbred C57BL | 7 | 2014 | 22128 | 0.050 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2006 | 342 | 0.050 |
Why?
|
Pneumonia, Bacterial | 1 | 2006 | 316 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2014 | 18927 | 0.050 |
Why?
|
Bone Marrow Transplantation | 1 | 2010 | 2692 | 0.050 |
Why?
|
Drugs, Chinese Herbal | 1 | 2004 | 143 | 0.050 |
Why?
|
Animals | 13 | 2014 | 168089 | 0.050 |
Why?
|
Alendronate | 1 | 2003 | 174 | 0.050 |
Why?
|
Primary Health Care | 1 | 2019 | 4679 | 0.050 |
Why?
|
Insulin Infusion Systems | 1 | 2024 | 217 | 0.050 |
Why?
|
Epithelial Cells | 1 | 2014 | 3671 | 0.050 |
Why?
|
DNA, Viral | 1 | 2008 | 2195 | 0.050 |
Why?
|
Safety | 1 | 2006 | 1151 | 0.050 |
Why?
|
Osteoporosis | 2 | 2003 | 1604 | 0.040 |
Why?
|
Male | 17 | 2024 | 360703 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2002 | 585 | 0.040 |
Why?
|
Cryopreservation | 1 | 2024 | 728 | 0.040 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2006 | 830 | 0.040 |
Why?
|
Cohort Studies | 4 | 2021 | 41496 | 0.040 |
Why?
|
Liver Transplantation | 1 | 2010 | 2332 | 0.040 |
Why?
|
Female | 17 | 2024 | 392552 | 0.040 |
Why?
|
Microscopy, Electron | 1 | 2002 | 2561 | 0.040 |
Why?
|
Models, Biological | 2 | 2005 | 9458 | 0.040 |
Why?
|
Gastrointestinal Tract | 1 | 2024 | 834 | 0.040 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2021 | 450 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2022 | 12159 | 0.040 |
Why?
|
Histocytochemistry | 1 | 1998 | 697 | 0.040 |
Why?
|
Adolescent | 8 | 2021 | 88300 | 0.040 |
Why?
|
Gastroesophageal Reflux | 1 | 2024 | 821 | 0.030 |
Why?
|
Pancreas | 1 | 2024 | 1684 | 0.030 |
Why?
|
New England | 1 | 2020 | 1052 | 0.030 |
Why?
|
Pseudomonas aeruginosa | 2 | 2022 | 1272 | 0.030 |
Why?
|
Forecasting | 1 | 2006 | 2928 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2021 | 1737 | 0.030 |
Why?
|
Survival Rate | 1 | 2010 | 12728 | 0.030 |
Why?
|
Young Adult | 4 | 2021 | 59222 | 0.030 |
Why?
|
Rabbits | 1 | 2002 | 4750 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2006 | 11067 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2006 | 5871 | 0.030 |
Why?
|
Kidney Transplantation | 1 | 2010 | 4242 | 0.030 |
Why?
|
Disease Models, Animal | 4 | 2004 | 18222 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2006 | 5250 | 0.030 |
Why?
|
Forced Expiratory Volume | 1 | 2020 | 1813 | 0.030 |
Why?
|
Kinetics | 1 | 2002 | 6312 | 0.030 |
Why?
|
Tenascin | 1 | 2014 | 61 | 0.030 |
Why?
|
Glucuronosyltransferase | 1 | 2014 | 132 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2024 | 4739 | 0.030 |
Why?
|
Hematopoietic Stem Cells | 1 | 2006 | 3390 | 0.030 |
Why?
|
Mice, 129 Strain | 1 | 2014 | 370 | 0.030 |
Why?
|
Retrospective Studies | 6 | 2018 | 80675 | 0.030 |
Why?
|
Mice, SCID | 1 | 1998 | 2621 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2002 | 2881 | 0.030 |
Why?
|
Mice, Inbred C3H | 1 | 2014 | 914 | 0.030 |
Why?
|
Respiratory Tract Infections | 1 | 2000 | 1009 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10088 | 0.030 |
Why?
|
Advance Care Planning | 1 | 2020 | 697 | 0.030 |
Why?
|
Patient Preference | 1 | 2020 | 927 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3634 | 0.020 |
Why?
|
Middle Aged | 7 | 2021 | 220858 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2021 | 2567 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3089 | 0.020 |
Why?
|
Oxygen | 1 | 2022 | 4228 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2002 | 4537 | 0.020 |
Why?
|
Pleura | 1 | 2012 | 244 | 0.020 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2014 | 630 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2014 | 1334 | 0.020 |
Why?
|
Insulin | 1 | 2024 | 6588 | 0.020 |
Why?
|
Collagen | 2 | 2012 | 2635 | 0.020 |
Why?
|
Macrophages | 2 | 2006 | 5755 | 0.020 |
Why?
|
Aged | 3 | 2021 | 169292 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2006 | 11512 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2019 | 2632 | 0.020 |
Why?
|
Antigens, CD | 1 | 1998 | 4009 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6486 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8837 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2021 | 22174 | 0.020 |
Why?
|
Time Factors | 2 | 2012 | 39957 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15841 | 0.020 |
Why?
|
Succinimides | 1 | 2005 | 81 | 0.020 |
Why?
|
Age Factors | 2 | 2018 | 18384 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8642 | 0.020 |
Why?
|
Fluoresceins | 1 | 2005 | 235 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 1996 | 3149 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10516 | 0.020 |
Why?
|
Mental Health | 1 | 2019 | 3251 | 0.010 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2006 | 328 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2022 | 7407 | 0.010 |
Why?
|
Vitamin K Deficiency | 1 | 2003 | 24 | 0.010 |
Why?
|
Densitometry | 1 | 2003 | 151 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13511 | 0.010 |
Why?
|
Animals, Wild | 1 | 2002 | 78 | 0.010 |
Why?
|
Toll-Like Receptors | 1 | 2006 | 575 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7965 | 0.010 |
Why?
|
North Carolina | 1 | 2002 | 324 | 0.010 |
Why?
|
HLA-B Antigens | 1 | 2003 | 317 | 0.010 |
Why?
|
Prospective Studies | 2 | 2024 | 54437 | 0.010 |
Why?
|
Chemokines | 1 | 2006 | 956 | 0.010 |
Why?
|
Infant | 1 | 2024 | 36170 | 0.010 |
Why?
|
Respiratory Function Tests | 1 | 2006 | 1685 | 0.010 |
Why?
|
Risk Assessment | 2 | 2018 | 24022 | 0.010 |
Why?
|
Th1 Cells | 1 | 2006 | 1042 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2002 | 781 | 0.010 |
Why?
|
Major Histocompatibility Complex | 1 | 2002 | 872 | 0.010 |
Why?
|
Bone Resorption | 1 | 2003 | 723 | 0.010 |
Why?
|
Vascular Patency | 1 | 2002 | 911 | 0.010 |
Why?
|
Viral Load | 1 | 2008 | 3328 | 0.010 |
Why?
|
Depression | 1 | 2019 | 8132 | 0.010 |
Why?
|
Inflammation | 1 | 1998 | 10759 | 0.010 |
Why?
|
Lectins | 1 | 2000 | 489 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2005 | 1783 | 0.010 |
Why?
|
Adipokines | 1 | 2000 | 307 | 0.010 |
Why?
|
Probability | 1 | 2003 | 2478 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 2005 | 1901 | 0.010 |
Why?
|
Fractures, Bone | 1 | 2009 | 2046 | 0.010 |
Why?
|
Burkholderia cepacia | 1 | 1997 | 22 | 0.010 |
Why?
|
Prognosis | 1 | 2018 | 29688 | 0.010 |
Why?
|
Collagen Type I | 1 | 2000 | 616 | 0.010 |
Why?
|
Treatment Failure | 1 | 2002 | 2643 | 0.010 |
Why?
|
Reference Values | 1 | 2003 | 4921 | 0.010 |
Why?
|
Drug Resistance, Multiple | 1 | 1997 | 255 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2018 | 64681 | 0.010 |
Why?
|
Administration, Oral | 1 | 2003 | 4015 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2003 | 4851 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2003 | 6223 | 0.010 |
Why?
|
Amino Acids | 1 | 2000 | 1703 | 0.010 |
Why?
|
Fractures, Spontaneous | 1 | 1996 | 231 | 0.010 |
Why?
|
Glycoproteins | 1 | 2000 | 2203 | 0.010 |
Why?
|
United States | 1 | 2021 | 72341 | 0.010 |
Why?
|
Child | 1 | 2021 | 80154 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2009 | 7400 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 15308 | 0.010 |
Why?
|
Antibiotic Prophylaxis | 1 | 1997 | 637 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2003 | 10756 | 0.010 |
Why?
|
Postoperative Care | 1 | 1997 | 1468 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2002 | 4373 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2003 | 12341 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2002 | 4574 | 0.000 |
Why?
|
Bacterial Infections | 1 | 1997 | 1390 | 0.000 |
Why?
|
C-Reactive Protein | 1 | 2000 | 3821 | 0.000 |
Why?
|
Peptides | 1 | 2000 | 4353 | 0.000 |
Why?
|
Respiration, Artificial | 1 | 1997 | 2631 | 0.000 |
Why?
|
Length of Stay | 1 | 1997 | 6417 | 0.000 |
Why?
|
Risk Factors | 2 | 2003 | 74241 | 0.000 |
Why?
|
Follow-Up Studies | 1 | 2003 | 39127 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 1996 | 26072 | 0.000 |
Why?
|
Concepts
(234)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(44)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_